GlaxoSmithKline and
Archemix Corp. have entered a worldwide strategic alliance to discover, develop and commercialize aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Aptamers are synthetized oligonucleotides, or short nucleic acid sequences, that bind to proteins with high affinity and specificity.
The alliance leverages Archemix’s expertise and intellectual property in the discovery and development of aptamer therapeutics and provides GSK with an option to license product candidates directed at seven different aptamer targets related to inflammatory disease.
Under the terms of the agreement, Archemix will receive $27.5 million in upfront payments, including a $6.5 million equity investment by GSK in the company. Archemix could also be eligible to receive as much as $200 million in development, regulatory and sales milestones for each of the seven aptamer therapeutics which may be discovered and developed as part of the alliance. Archemix would also receive tiered royalties on worldwide sales of products that may result from the alliance.
Archemix will be responsible for the discovery and development of the aptamer therapeutics through clinical proof of mechanism, unless GSK chooses to exercise its option earlier. GSK would then have an exclusive license to drug candidates developed under each program for further development and commercialization on a worldwide basis. Archemix will have the right to develop and commercialize any aptamer therapeutics that GSK does not select.
“We are very excited about this collaboration with GSK. GSK is an outstanding partner with leadership and expertise in inflammation, and we look forward to expanding our efforts in inflammation where aptamers could offer novel options to treat disease,” said Errol DeSouza, Ph.D., president and chief executive officer of Archemix. “This is another step forward in our strategy to leverage our intellectual property estate together with our significant internal capabilities in order to develop aptamers for a variety of therapeutic areas with key partners who are experts in their field.”
"This innovative multi-target drug-discovery deal is an important extension of our externalization strategy and provides GSK with an outstanding opportunity to work with the world leader in aptamer discovery and development," said Jose Carlos Gutierrez-Ramos, Ph.D., senior vice president and Head of the Immuno-Inflammation Centre of Excellence for Drug Discovery in GSK. "The application of aptamers with their unique properties is an exciting opportunity that holds enormous potential for the treatment of many devastating diseases of the immune system."
Magazine
